RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas. Its Ebola vaccine has been approved for use, and the company’s meningitis and a meningococcal vaccines are near-NDA stage. Both candidates have demonstrated superior safety profiles and immunogenicity in their Phase III trials. CanSino is the seventh China biopharma, and the first vaccine company, to IPO in Hong Kong under its pre-revenue rules.
Source: China Biotoday
